LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | GW843682X | 0.12 | uM | LJP6 | 72 | hr | 1401 | 2267 | 4168 | 0.5435 | 0.3565 |
| SK-BR-3 | GW843682X | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1457 | 4168 | 0.3490 | 0.0225 |
| SK-BR-3 | GW843682X | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1237 | 4168 | 0.2965 | -0.0775 |
| SK-BR-3 | GW843682X | 10 | uM | LJP6 | 72 | hr | 1401 | 1734 | 4168 | 0.4157 | 0.1431 |
| SK-BR-3 | HG-5-113-01 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 1494 | 4245 | 0.3516 | 0.0379 |
| SK-BR-3 | HG-5-113-01 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 1313 | 4245 | 0.3093 | -0.0421 |
| SK-BR-3 | HG-5-88-01 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3097 | 4168 | 0.7436 | 0.6564 |
| SK-BR-3 | HG-5-88-01 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 3487 | 4168 | 0.8366 | 0.7854 |
| SK-BR-3 | HG-5-88-01 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 3630 | 4168 | 0.8713 | 0.8325 |
| SK-BR-3 | HG-5-88-01 | 10 | uM | LJP6 | 72 | hr | 1401 | 2100 | 4168 | 0.5038 | 0.2930 |
| SK-BR-3 | HG-6-64-01 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 3544 | 4168 | 0.8505 | 0.8041 |
| SK-BR-3 | HG-6-64-01 | 0.37 | uM | LJP6 | 72 | hr | 1401 | 3319 | 4168 | 0.7952 | 0.7259 |
| SK-BR-3 | Seliciclib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4169 | 4245 | 0.9826 | 0.9786 |
| SK-BR-3 | Seliciclib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4234 | 4245 | 0.9990 | 1.0004 |
| SK-BR-3 | Seliciclib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 3763 | 4245 | 0.8864 | 0.8542 |
| SK-BR-3 | Seliciclib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3235 | 4245 | 0.7609 | 0.6836 |
| SK-BR-3 | AT-7519 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 1469 | 4168 | 0.3528 | 0.0307 |
| SK-BR-3 | AT-7519 | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1174 | 4168 | 0.2819 | -0.1064 |
| SK-BR-3 | AT-7519 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 711 | 4168 | 0.1708 | -0.3524 |
| SK-BR-3 | AT-7519 | 10 | uM | LJP6 | 72 | hr | 1401 | 486 | 4168 | 0.1167 | -0.4930 |
| SK-BR-3 | AZD7762 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1112 | 4168 | 0.2665 | -0.1380 |
| SK-BR-3 | AZD7762 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1020 | 4168 | 0.2452 | -0.1849 |
| SK-BR-3 | AZD8055 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 1460 | 4168 | 0.3504 | 0.0264 |
| SK-BR-3 | Neratinib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 1408 | 4245 | 0.3327 | 0.0029 |
| SK-BR-3 | Neratinib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 1511 | 4245 | 0.3564 | 0.0471 |